RTP Mobile Logo
Oncology Today with Dr Neil Love: Novel Immunotherapeutic Strategies in Melanoma (Audio Interview)
Released December 2022

Featuring an interview with Dr Omid Hamid. Published December 13, 2022. (Audio Interview)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of melanoma.

    LEARNING OBJECTIVES

    • Assess available efficacy and safety findings with anti-LAG-3 antibodies in combination with anti-PD-1/PD-L1 antibodies for patients with advanced melanoma in order to optimally integrate this strategy into the treatment armamentarium.
    • Develop an understanding of the scientific rationale for the development of autologous tumor-infiltrating lymphocyte therapy as a means to eliminate cancer cells, and appraise existing data with and the potential role of this approach in the treatment of advanced melanoma.
    • Appreciate the biologic rationale for combining immune checkpoint inhibitors with agents targeting the VEGF axis in patients with advanced melanoma, and assess published clinical trial findings with this strategy to discern whether it has a current or potential role in practice.
    • Recognize common adverse events associated with available and investigational novel therapies for melanoma, and advise patients about the potential for complications.
    • Recall the design of ongoing clinical trials evaluating novel immunotherapeutic strategies for advanced melanoma, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Presentations Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Omid Hamid, MD
    Chief of Research/Immuno-Oncology
    The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate
    Co-Director, Cutaneous Malignancy Program
    Cedars-Sinai Cancer
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Alkermes, Amgen Inc, Bactonix, BeiGene Ltd, BioAtla, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, Georgiamune, GigaGen, GlaxoSmithKline, Grit Bio, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Instil Bio, IO Biotech, Iovance Biotherapeutics, Janssen Biotech Inc, KSQ Therapeutics, Merck, Moderna, Novartis, Obsidian Therapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Tempus, Zelluna Immunotherapy AS; Contracted Research: Akeso Inc, Amgen Inc, Arcus Biosciences, BioAtla, Bristol-Myers Squibb Company, Chinook Therapeutics, CytomX Therapeutics, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Iovance Biotherapeutics, Merck, Merck Serono, Moderna, NextCure, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Seagen Inc, Zelluna Immunotherapy AS; Speakers Bureau: Bristol-Myers Squibb Company, Immunocore, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc; Nonrelevant Financial Relationship: Vial.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc, Merck, and Regeneron Pharmaceuticals Inc.

    Release date: December 2022
    Expiration date: December 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):